Gestonorone acetate
Подписчиков: 0, рейтинг: 0
Not to be confused with Gestonorone caproate.
| Clinical data | |
|---|---|
| Other names | Gestronol acetate; Norhydroxyprogesterone acetate; 17α-Hydroxy-19-norprogesterone 17α-acetate; 17α-Acetoxy-19-norprogesterone; 17α-Hydroxy-19-norpregn-4-ene-3,20-dione 17α-acetate |
| Drug class | Progestin; Progestogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.046.242 |
| Chemical and physical data | |
| Formula | C22H30O4 |
| Molar mass | 358.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gestonorone acetate, or gestronol acetate, also known as norhydroxyprogesterone acetate, is a progestin of the 19-norprogesterone and 17α-hydroxyprogesterone groups which was developed in the early 1960s but was never marketed. It is the C17α acetate ester of gestronol (17α-hydroxy-19-norprogesterone).
Gestonorone acetate has been found to consistently inhibit ovulation at an oral dosage of 10 mg/day in combination with 50 μg/day oral ethinylestradiol. Weak or no endometrial effects were observed at an oral dosage of 100 mg/day, basal vacuoles appeared at 130 to 140 mg/day, and full endometrial secretory transformation occurred at 220 mg/day.